The buy also represents the first sale of a neuroscience asset by Pfizer since its announcement earlier this year of plans to discontinue research in neuroscience discovery and drug development. In Phase 1 trials, Pfizer's candidate was shown to be safe, and Phase 1b showed the drug could affect …

Link to Full Article: Read Here

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!